您好, 访客   登录/注册
  •  > 中国论文网 > 
  • 医学论文  > 
  • 匹维溴铵、蒙脱石散及双歧杆菌四联活菌片治疗腹泻型肠易激综合征的临床疗效

匹维溴铵、蒙脱石散及双歧杆菌四联活菌片治疗腹泻型肠易激综合征的临床疗效

来源:用户上传      作者:周丹 谢欣城 朱元东

  [摘要] 目的 ^察匹维溴铵、蒙脱石散联合双歧杆菌四联活菌片治疗腹泻型肠易激综合征的临床疗效。 方法 收集2019年6月至2020年8月杭州市西溪医院门诊及住院腹泻型肠易激综合征(IBS-D)患者80例,分为两组,每组各40例,对照组予以匹维溴铵联合蒙脱石散口服,观察组予以匹维溴铵、蒙脱石散联合双歧杆菌四联活菌片口服,分别在治疗前后对患者的IBS症状严重程度评分(IBS-SSS),生存质量评分(IBS-QL),并在治疗结束时进行疗效评判,同时记录可能相关的不良反应。 结果 治疗后,观察组的IBS-SSS为(18.06±4.53)分,低于对照组的(20.23±6.03)分,两组比较,差异有统计学意义(P<0.001),观察组的IBS-QL为(89.88±1.24)分,高于对照组的(82.53±1.68)分,两组比较,差异有统计学意义(P<0.001);观察组的总有效率(95.00%)高于对照组(75.00%),两组比较,差异有统计学意义(χ2=5.262,P<0.05)。对照组发生不良反应2例,观察组发生不良反应1例,两组比较,差异无统计学意义(P=0.974,P>0.05)。 结论 采用匹维溴铵、蒙脱石散联合双歧杆菌四联活菌片治疗腹泻型肠易激综合征的临床效果确切。
  [关键词] 匹维溴铵;蒙脱石散;双歧杆菌四联活菌片;腹泻型;肠易激综合征
  [中图分类号] R574.4 [文献标识码] B [文章编号] 1673-9701(2022)13-0031-03
  [Abstract] Objective To observe the clinical efficacy of pinaverium bromide, montmorillonite powder combined with bifidobacterium quadruple viable bacteria tablets in treating diarrhea-type irritable bowel syndrome. Methods A total of 80 cases of outpatient and inpatient diarrheal irritable bowel syndrome (IBS-D) in Hangzhou Xixi Hospital from June 2019 to August 2020 were collected, with 40 cases in each group.The control group took pinaverium bromide combined with montmorillonite powder orally.The observation group took pinaverium bromide, montmorillonite powder,and bifidobacterium quadruple viable bacteria tablets orally. The patients′ IBS symptom severity score (IBS-SSS) and quality of life score (IBS-QL) were scored before and after treatment. The efficacy was evaluated at the end of the treatment, and the possible related adverse reactions were recorded. Results After treatment, the IBS-SSS (18.06±4.53)points of the observation group was lower than the IBS-SSS(20.23±6.03)points of the control group,and the difference between the two groups was statistically significant(P<0.001). The IBS-QL (89.88±1.24)points of the observation group was higher than the IBS-QL (82.53±1.68) points of the control group. The difference between the two groups was statistically significant(P<0.001). The total efficacy rate of the observation group (95.00%) was higher than the control group (75.00%),and the difference between the two groups was statistically significant(χ2=5.262,P<0.05).There were 2 cases of adverse reactions in the control group and 1 case in the observation group. There was no statistically significant difference between the two groups(P=0.974,P>0.05). Conclusion The pinaverium bromide, montmorillonite powder combined with bifidobacterium quadruple viable bacteria tablets, has a clinical effect on treating diarrhea-type irritable bowel syndrome.

nlc202206161043



转载注明来源:https://www.xzbu.com/6/view-15433754.htm

相关文章

服务推荐